Back to today’s briefing

Story perspectives

MR-141 Boosts Near Vision in Phase III Trial

7/3/2025

34 7

Summary

Story summary

In the Phase III VEGA-3 trial, MR-141 (phentolamine ophthalmic solution 0.75%) remarkably enhanced near visual acuity in 27.2% of patients, outpacing the 11.5% improvement seen with placebo. With a reassuring safety profile and no serious side effects, Viatris and Opus Genetics are gearing up to submit their FDA application by late 2025.

1 of 1

Story summary

In the Phase III VEGA-3 trial, MR-141 (phentolamine ophthalmic solution 0.75%) remarkably enhanced near visual acuity in 27.2% of patients, outpacing the 11.5% improvement seen with placebo. With a reassuring safety profile and no serious side effects, Viatris and Opus Genetics are gearing up to submit their FDA application by late 2025.